Mirada Solutions and Hitachi Medical Systems America Announce the Release of a New Edition of Fusion7D for the AVIA Workstation
25 June 2004 - 4:00AM
PR Newswire (US)
Mirada Solutions and Hitachi Medical Systems America Announce the
Release of a New Edition of Fusion7D for the AVIA Workstation
OXFORD, England, June 24 /PRNewswire-FirstCall/ -- Mirada Solutions
Ltd. (a subsidiary of CTI Molecular Imaging, Inc.), leaders in
software for molecular imaging, and Hitachi Medical Systems America
(HMSA) announced today the release of the latest edition of
Fusion7D(TM) for the AVIA(TM) workstation and plans for extending
further PET and PET/CT analysis tools to Hitachi customers.
Fusion7D is the leading image fusion and analysis package for PET
and PET/CT. It is fully integrated onto the AVIA multi-modality
workstation, bringing advanced PET analysis and image fusion
software into the hands of PET practitioners. This latest release
provides a range of new features and further streamlines the review
and analysis workflow for PET and PET/CT. Future product extension
plans revealed by the companies include offering Mirada's PET/CT
viewer and RTist(TM) applications on AVIA(1). RTist provides a
complete set of contouring and structure delineation tools for
PET/CT and fusion imaging with support for DICOM RT structure sets.
This enables fusion data to be contoured and sent (along with
images) directly to treatment planning systems, further positioning
PET/CT as an integrated oncology tool. Christian P. Behrenbruch
Ph.D., President of Mirada Solutions, commented "Hitachi was our
first Fusion7D OEM customer and we are pleased to be continuing the
product line by adding new functions like support for radiation
therapy. Our timing of this release of Fusion7D coincides with the
announcement of Hitachi's new PET/CT scanner. We look forward to
providing new and additional software tools for PET/CT review and
therapy to work with this outstanding system." Bill Bishop, Vice
President for Business Development at HMSA, stated "Hitachi
continues to enjoy an excellent and highly productive relationship
with the team at Mirada. The additional tools and product
structuring helps to position our AVIA workstation as a winning
platform for PET, PET/CT and multimodal review." About Mirada
Solutions: Mirada Solutions Limited, a wholly owned subsidiary of
CTI Molecular Imaging, is a leading developer of software and
analytical tools for medical imaging workstations, OEM imaging
platforms and pharmaceutical applications. Mirada's unique products
aid in better detection, diagnosis and management of disease
through the application of powerful algorithms, quantification
tools and image analysis. Additional information is available at
http://www.mirada-solutions.com/ . About CTI Molecular Imaging: CTI
Molecular Imaging, Inc. is a leading supplier of products and
services for positron emission tomography (PET), a diagnostic
imaging technology used in the detection and treatment of cancer,
cardiac disease and neurological disorders. Additional information
is available at: http://www.ctimi.com/ . Certain matters discussed
in this press release constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements may be identified by words
such as "believe," "assume," "expect," "anticipate," "intend,"
"estimate" or similar expressions, and any other statements that
necessarily depend on future events. Forward-looking statements
involve a number of risks and uncertainties and there can be no
assurance that any forward-looking statements will prove to be
accurate. Various factors could cause actual results to differ
materially from those anticipated in the forward-looking
statements. CTI undertakes no obligation to update or revise any
forward- looking statements. Further information regarding risks,
uncertainties and other factors that could adversely affect CTI or
cause actual results to differ materially from those anticipated in
forward-looking statements are included in CTI's Annual Report on
Form 10-K for the fiscal year ended September 30, 2003, Quarterly
Report on Form 10-Q for the quarter ended March 31, 2004. Notes:
(1) RTist integration planned for release in Q4, 2004. DATASOURCE:
CTI Molecular Imaging, Inc., Mirada Solutions Ltd. CONTACT: Clare
F. Jones of Mirada Solutions Ltd., +44-1865-265-500; or Michael A.
Lawless of CTI Molecular Imaging, Inc., +1-865-218-2000 Web site:
http://www.ctimi.com/ http://www.mirada-solutions.com/
Copyright